3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Genitourinary
1
Conditions
Multiple Myeloma
10
Renal Insufficiency
1
Recurrence
1
Neoplasms, Plasma Cell
1
Kidney Failure, Chronic
1
Interventions
Paclitaxel
2
Kidney Transplantation
2
Cyclophosphamide
2
Azacitidine
2
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pomalidomide
1
pevonedistat
1
osimertinib
1
mirabegron
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
dabrafenib
1
copanlisib
1
belinostat
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Topotecan
1
Taxes
1
Sitagliptin Phosphate
1
Rituximab
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Methotrexate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Renal Insufficiency
×
belantamab mafodotin
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled